BioNTech
Founded Year
2008Stage
PIPE - II | IPOTotal Raised
$771.5MMarket Cap
25.18BStock Price
101.80Revenue
$0000About BioNTech
BioNTech focuses on the development of individualized immunotherapies for the treatment of cancer and infectious diseases within the biotechnology sector. The company's main offerings include mRNA therapeutics, engineered cell therapies, and a suite of antibody and small molecule immunomodulators designed for precision medicine. BioNTech's products are aimed at harnessing the power of the immune system to fight serious illnesses. It was founded in 2008 and is based in Mainz, Germany.
Loading...
Loading...
Research containing BioNTech
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioNTech in 2 CB Insights research briefs, most recently on Aug 8, 2023.
BioNTech Patents
BioNTech has filed 271 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- immunology
- immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/28/2021 | 9/3/2024 | Grant |
Application Date | 6/28/2021 |
|---|---|
Grant Date | 9/3/2024 |
Title | |
Related Topics | |
Status | Grant |
Latest BioNTech News
Nov 3, 2024
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday Posted by MarketBeat News on Nov 3rd, 2024 BioNTech ( NASDAQ:BNTX – Get Free Report ) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link . BioNTech ( NASDAQ:BNTX – Get Free Report ) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter last year, the business posted ($0.86) earnings per share. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. On average, analysts expect BioNTech to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year. Get BioNTech alerts: BioNTech Stock Down 1.4 % BioNTech stock opened at $111.48 on Friday. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock has a market cap of $26.51 billion, a PE ratio of -49.33 and a beta of 0.26. The stock’s fifty day moving average is $109.72 and its two-hundred day moving average is $95.77. Wall Street Analysts Forecast Growth Want More Great Investing Ideas?
BioNTech Frequently Asked Questions (FAQ)
When was BioNTech founded?
BioNTech was founded in 2008.
Where is BioNTech's headquarters?
BioNTech's headquarters is located at An der Goldgrube 12, Mainz.
What is BioNTech's latest funding round?
BioNTech's latest funding round is PIPE - II.
How much did BioNTech raise?
BioNTech raised a total of $771.5M.
Who are the investors of BioNTech?
Investors of BioNTech include Coalition for Epidemic Preparedness Innovations, Temasek, Bill & Melinda Gates Foundation, Sanofi, Redmile Group and 9 more.
Who are BioNTech's competitors?
Competitors of BioNTech include Ethris and 2 more.
Loading...
Compare BioNTech to Competitors
Inscripta is a digital genome engineering company focused on the biomanufacturing sector. The company offers a platform and tools for optimizing strains in bioengineering processes, utilizing technologies such as Directed Evolution, CRISPR, and Machine Learning. Inscripta's services cater to the biotechnology and bioeconomy sectors, aiming to enhance biomanufacturing scalability and cost-effectiveness. Inscripta was formerly known as Muse Biotechnology. It was founded in 2015 and is based in Pleasanton, California.
Mammoth Biosciences is a biotechnology company specializing in the development of in vivo gene editing therapeutics and diagnostics using CRISPR technology. The company offers a range of services including precision gene editing with novel CRISPR-Cas enzymes, protein discovery and engineering, and a revolutionary molecular diagnostics platform. Mammoth Biosciences primarily serves the healthcare sector, with a focus on genetic medicine and collaborations with leading pharmaceutical companies. Mammoth Biosciences was formerly known as Apheleia Diagnostics. It was founded in 2017 and is based in Brisbane, California.
Alia Therapeutics focuses on developing gene-editing medicines within the biotechnology sector. The company specializes in creating therapies that correct genetic errors in patients' cells to treat rare genetic diseases. Alia Therapeutics' core technologies enhance the precision of genetic modifications It was founded in 2018 and is based in Milan, Italy.
ReCode Therapeutics operates as a genetic medicines company in the biotechnology industry. The company's main services include the development of mRNA and gene correction therapeutics, utilizing their selective organ targeting (SORT) lipid nanoparticle (LNP) platform. This platform enables highly targeted delivery of genetic medicines to organs, tissues, and cells beyond the liver. It was founded in 2015 and is based in Menlo Park, California.
Ethris develops messenger ribonucleic acid (mRNA) therapeutics with a focus on respiratory diseases and vaccines. The technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. It was founded in 2009 and is based in Planegg, Germany.
HDT Bio is a clinical stage biotechnology company focused on developing advanced RNA vaccine products for infectious diseases and cancers. The company's main offerings include a proprietary LION™ technology and self-amplifying RNA (repRNA) vaccines designed to activate the immune system and provide enhanced safety, potency, and durability. It was founded in 2018 and is based in Seattle, Washington.
Loading...